Farrukh Awan, MD

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Farrukh Awan, MD, delves into CAR T-cell therapy and its impact on the chronic lymphocytic leukemia treatment paradigm.

Farrukh Awan, MD, discuses the evolving role of bispecific antibodies in the treatment paradigm of diffuse large B-cell lymphoma.

Farrukh Awan, MD, discusses the potential use of BTK inhibitors in the management of mantle cell leukemia.

Farrukh Awan, MD, discusses the current use of BTK inhibitors in the management of chronic lymphocytic leukemia and important factors to consider when determining the best treatment strategy.

Farrukh Awan, MD, discusses the evolution of treating frontline chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses remaining questions regarding the use of BTK inhibitors and CD20-directed monoclonal antibodies in chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses questions regarding combination therapies in chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses the utilization of acalabrutinib in patients with chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses the need for time-limited treatments in patients with chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses the role of chemotherapy in the treatment of patients with chronic lymphocytic leukemia (CLL).